Our present data confirm and extend previous observations regarding the effect of targeted therapies on the COVID specific immune response in RA; the levels of anti-S antibodies were significantly lower among patients treated with TNF-α or IL-6-inhibitor than that of the healthy donors’ (19–22). This evidence concerns the gene IL6 and rheumatoid arthritis.